Read more about the article Allot Allows Telecom Providers to Leverage Their Networks for Increased Revenues; We view Allot`s Mobile Network Security operations as a growth engine for the company’s revenues in the coming years; we initiate coverage on Allot at a share price target of $12.0

Allot Allows Telecom Providers to Leverage Their Networks for Increased Revenues; We view Allot`s Mobile Network Security operations as a growth engine for the company’s revenues in the coming years; we initiate coverage on Allot at a share price target of $12.0

 

Continue ReadingAllot Allows Telecom Providers to Leverage Their Networks for Increased Revenues; We view Allot`s Mobile Network Security operations as a growth engine for the company’s revenues in the coming years; we initiate coverage on Allot at a share price target of $12.0
Read more about the article DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

Continue ReadingDNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.
Read more about the article RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59

RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59

Continue ReadingRedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59
Read more about the article Energix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05.

Energix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05.

Continue ReadingEnergix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05.